Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.64
-0.06 (-1.05%)
Sep 2, 2026, 4:00 PM EDT - Market closed
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.84 billion as of September 2, 2026. Its market cap has increased by 130.70% in one year.
Market Cap
1.84B
Enterprise Value
1.44B
1-Year Change
130.70%
Ranking
Category
Stock Price
$5.64
ChartMarket Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.84B, an increase of 166.17%. That is a compound annual growth rate of 17.91%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 2, 2026 | 1.84B | 21.98% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Vir Biotechnology | 1.97B |
| Immunocore Holdings | 1.90B |
| Maravai LifeSciences Holdings | 1.90B |
| GH Research | 1.88B |
| Lakefront Biotherapeutics NV | 1.86B |
| Inhibrx Biosciences | 1.83B |
| Kardigan | 1.83B |
| Syndax Pharmaceuticals | 1.79B |